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A “Win-Win” for
Peripheral Vascular Intervention*
Christopher J. White, MD
New Orleans, Louisiana
The physicians, hospitals, and particularly the sponsors of
“Safety of Contemporary Percutaneous Peripheral Arterial
Interventions in the Elderly: Insights from the Blue Cross
Blue Shield of Michigan Cardiovascular Consortium Pe-
ripheral Vascular Intervention Registry” are to be congrat-
ulated for their innovative, forward-looking efforts to im-
prove the quality of care for lower-extremity peripheral
vascular disease (LE-PVD) patients in Michigan (1). Their
report is based upon a large “real world” sample of heteroge-
neous patients treated in 18 hospitals (i.e., university-based,
governmental, large multispecialty systems, and community
hospitals) by a variety of physician specialists practicing periph-
eral vascular intervention (PVI). The primary outcome, which
confirms the safety of PVI in elderly patients, will inform the
national LE-PVD quality of care debate and impact future
guideline documents.
See page 694
To analyze the risk of PVI associated with age, the
authors segregated 7,769 consecutive LE-PVD patients
into 3 age groups: 1) 70 years (52%); 2) 70 to 79 years
(30%); and 3) 80 years (18%). Approximately two-thirds
of the patients had chronic limb ischemia (claudication),
with the remainder treated for critical limb ischemia (rest
pain or limb salvage). Elderly patients were quite different
from the younger groups, according to the demographic
data shown in Table 1 in Plaisance et al. (1), with over-
representation of several important comorbidities (female
sex, low body weight, hypertension, heart failure, cerebro-
vascular disease, and anemia). The younger groups had a
higher percentage with tobacco abuse, diabetes, hyperlipid-
emia, pulmonary disease, and dialysis. These “real world”
differences are a major strength of this large registry data-
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The data show that, as LE-PVD patients get older, they
develop more advanced atherosclerotic lesions that require
more complex PVI procedures. Percutaneous, nonsurgical
treatment of increasingly complex LE-PVD was associated
with a slightly lower success rate and more vascular access
complications than was seen in the younger groups. The
lower success rate might have been related to the unbalanced
excess of 2 procedure variables: 1) more complex below-knee
revascularization procedures were performed in elderly pa-
tients; and 2) more antegrade femoral access procedures were
performed in elderly patients. In contrast to the retrograde
femoral access technique, antegrade common femoral artery
access is a more challenging technique that requires additional
training and skill and does not allow the use of vascular closure
devices. The more difficult antegrade access is preferred/
required for complex below-knee interventions that were more
commonly performed in elderly patients. The excess of these
adverse variables in elderly patients and their potential linkage
(one is associated with the other) makes risk adjustment and
direct comparisons among the age groups more difficult than
for a controlled study.
The major finding of this report, however, was that PVI
in elderly patients (age 80 years) was not independently
associated with an excess of major adverse cardiovascular
events, contrast induced nephropathy, transfusion, or am-
putation (1). The data support a trend in clinical practice of
adopting an “endovascular-first” approach to patients with
LE-PVD requiring revascularization. As the authors point
out, selecting PVI as the initial revascularization procedure
avoids the greater morbidity and mortality of open surgical
procedures and rarely, if ever, precludes a later attempt at
surgery if necessary. Based upon what now seems to have
been an incorrect perception of increased procedure risk,
elderly patients with LE-PVD should not be denied PVI
that might improve their quality of life by reducing pain and
improving their ability to ambulate and exercise.
This report also raises a separate issue related to national
efforts at improving overall quality of care by encouraging
appropriate use and improving patient outcomes. The Blue
Cross Blue Shield of Michigan Cardiovascular Consortium
Peripheral Vascular Intervention (BMC2 PVI) Registry is a
unique collaboration to evaluate evidence-based disease
management in support of improving quality of care and
patient outcomes. The stakeholders in this venture are a
private insurer (Blue Cross Blue Shield of Michigan), a
consortium of 18 Michigan hospitals (Online Appendix A
in Plaisance et al.) (1), and clinician investigators who
agreed to collaborate in this effort. The project was funded
with laudable foresight by an unrestricted grant from Blue
Cross Blue Shield of Michigan. The goal of the BMC2 PVI
registry was to demonstrate that health outcomes in vascular
patients could be improved by systematically collecting,
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703analyzing, and reporting real-world patient data. The reg-
istry data can be used to provide feedback that can result in
improvement in resource use. One obvious example in this
dataset is the disparity in the use of statins among elderly
PVI patients. It is now accepted that statin therapy is
beneficial and cost-effective in elderly patients (2). The next
step will be for the consortium to provide feedback and
education to effect a change in prescribing statins to elderly
patients.
A major issue for any large registry is controlling the
quality and reliability of the data collected. The BMC2 PVI
registry went to some lengths to ensure good data quality
with a multistep review process, data checks at several
stages, and a twice yearly on-site audit. The authors appro-
priately acknowledge the limitations of analyzing heteroge-
neous, self-reported, observational data without adjudica-
tion of outcomes. The lack of control groups makes
performing some comparison analyses difficult. For exam-
ple, there will be a strong selection bias among patients
receiving open surgery compared with PVI that will limit
any comparison of these populations. These groups might
be so different with regard to comorbidities that post hoc
risk adjustment will be very difficult if not impossible to
perform.
The best part of this story is that a partnership that
includes a major healthcare insurer, physicians, and hospi-
tals resulted in the collection, analysis, and publication of
valuable data representing the quality of health care for
LE-PVD patients. It is important to reassure providers that
PVI procedures should not be withheld from very elderlyatients for fear of increased procedure risk. This report
rovides a benchmark for PVI outcomes and encourages the
doption of continuous quality improvement initiatives across
he BMC2 system. Finally, and most importantly, the BMC2
VI registry is an excellent model for a “win-win” strategy for
ll stakeholders involved in the care of patients with vascular
isease. Kudos to the doctors, hospital administrators, and the
eadership of Blue Cross Blue Shield of Michigan for figuring
ut how to collaboratively align their incentives in the best
nterests of their patients.
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